DOCSLIB.ORG

Medstar Family Choice - Maryland Healthchoice Prescribing Guide 2020 (710)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Medstar Family Choice - Maryland Healthchoice Prescribing Guide 2020 (710) MedStar Family Choice - Maryland HealthChoice Prescribing Guide 2020 (710) (10/01/2020) INTRODUCTION .............................................................................................................................................................................. 5 NONDISCRIMINATION STATEMENT ............................................................................................................................................. 5 PREFACE ......................................................................................................................................................................................... 7 PHARMACY AND THERAPEUTICS (P&T) COMMITTEE .............................................................................................................. 8 PRODUCT SELECTION CRITERIA ................................................................................................................................................. 8 GENERIC AVAILABILITY ................................................................................................................................................................ 8 GENERIC SUBSTITUTION .............................................................................................................................................................. 8 MAIL SERVICE PRESCRIPTIONS .................................................................................................................................................. 9 MEDICAL EXCEPTION .................................................................................................................................................................... 9 PRIOR AUTHORIZATION (PA) ....................................................................................................................................................... 9 Drugs requiring Prior Authorization ............................................................................................................................................. 9 MANAGED DRUG LIMITATIONS (MDL) ....................................................................................................................................... 10 STEP THERAPY (ST) .................................................................................................................................................................... 12 OVER-THE-COUNTER (OTC) DRUG COVERAGE ...................................................................................................................... 13 EDITOR .......................................................................................................................................................................................... 16 NOTICE .......................................................................................................................................................................................... 16 LEGEND ......................................................................................................................................................................................... 17 ANALGESICS ................................................................................................................................................................................ 18 NSAIDs .................................................................................................................................................................................. 18 NSAIDs, TOPICAL ................................................................................................................................................................ 18 COX-2 INHIBITORS .............................................................................................................................................................. 18 GOUT .................................................................................................................................................................................... 18 OPIOID ANALGESICS .......................................................................................................................................................... 18 NON-OPIOID ANALGESICS ................................................................................................................................................. 19 VISCOSUPPLEMENTS......................................................................................................................................................... 19 ANTI-INFECTIVES ......................................................................................................................................................................... 19 ANTIBACTERIALS ................................................................................................................................................................ 20 ANTIFUNGALS ..................................................................................................................................................................... 21 ANTIMALARIALS .................................................................................................................................................................. 21 ANTIRETROVIRAL AGENTS................................................................................................................................................ 21 ANTITUBERCULAR AGENTS .............................................................................................................................................. 22 ANTIVIRALS ......................................................................................................................................................................... 22 MISCELLANEOUS ................................................................................................................................................................ 23 ANTINEOPLASTIC AGENTS ........................................................................................................................................................ 23 ALKYLATING AGENTS ........................................................................................................................................................ 23 ANTIMETABOLITES ............................................................................................................................................................. 23 HORMONAL ANTINEOPLASTIC AGENTS .......................................................................................................................... 23 KINASE INHIBITORS ............................................................................................................................................................ 24 TOPOISOMERASE INHIBITORS ......................................................................................................................................... 25 MISCELLANEOUS ................................................................................................................................................................ 25 1 CARDIOVASCULAR ...................................................................................................................................................................... 25 ACE INHIBITORS ................................................................................................................................................................. 25 ACE INHIBITOR/CALCIUM CHANNEL BLOCKER COMBINATIONS.................................................................................. 26 ACE INHIBITOR/DIURETIC COMBINATIONS ..................................................................................................................... 26 ADRENOLYTICS, CENTRAL ................................................................................................................................................ 26 ALDOSTERONE RECEPTOR ANTAGONISTS.................................................................................................................... 26 ALPHA BLOCKERS .............................................................................................................................................................. 26 ANGIOTENSIN II RECEPTOR ANTAGONISTS/DIURETIC COMBINATIONS .................................................................... 26 ANGIOTENSIN II RECEPTOR ANTAGONIST/CALCIUM CHANNEL BLOCKER COMBINATIONS ................................... 27 ANGIOTENSIN II RECEPTOR ANTAGONIST/CALCIUM CHANNEL BLOCKER/DIURETIC COMBINATIONS ................. 27 ANTIARRHYTHMICS ............................................................................................................................................................ 27 ANTILIPEMICS ..................................................................................................................................................................... 27 BETA-BLOCKERS ................................................................................................................................................................ 28 BETA-BLOCKER/DIURETIC COMBINATIONS .................................................................................................................... 28 CALCIUM CHANNEL BLOCKERS.......................................................................................................................................
Load more

Recommended publications
  • AHFS Pharmacologic-Therapeutic Classification System
    AHFS Pharmacologic-Therapeutic Classification System Abacavir 48:24 - Mucolytic Agents - 382638 8:18.08.20 - HIV Nucleoside and Nucleotide Reverse Acitretin 84:92 - Skin and Mucous Membrane Agents, Abaloparatide 68:24.08 - Parathyroid Agents - 317036 Aclidinium Abatacept 12:08.08 - Antimuscarinics/Antispasmodics - 313022 92:36 - Disease-modifying Antirheumatic Drugs - Acrivastine 92:20 - Immunomodulatory Agents - 306003 4:08 - Second Generation Antihistamines - 394040 Abciximab 48:04.08 - Second Generation Antihistamines - 394040 20:12.18 - Platelet-aggregation Inhibitors - 395014 Acyclovir Abemaciclib 8:18.32 - Nucleosides and Nucleotides - 381045 10:00 - Antineoplastic Agents - 317058 84:04.06 - Antivirals - 381036 Abiraterone Adalimumab; -adaz 10:00 - Antineoplastic Agents - 311027 92:36 - Disease-modifying Antirheumatic Drugs - AbobotulinumtoxinA 56:92 - GI Drugs, Miscellaneous - 302046 92:20 - Immunomodulatory Agents - 302046 92:92 - Other Miscellaneous Therapeutic Agents - 12:20.92 - Skeletal Muscle Relaxants, Miscellaneous - Adapalene 84:92 - Skin and Mucous Membrane Agents, Acalabrutinib 10:00 - Antineoplastic Agents - 317059 Adefovir Acamprosate 8:18.32 - Nucleosides and Nucleotides - 302036 28:92 - Central Nervous System Agents, Adenosine 24:04.04.24 - Class IV Antiarrhythmics - 304010 Acarbose Adenovirus Vaccine Live Oral 68:20.02 - alpha-Glucosidase Inhibitors - 396015 80:12 - Vaccines - 315016 Acebutolol Ado-Trastuzumab 24:24 - beta-Adrenergic Blocking Agents - 387003 10:00 - Antineoplastic Agents - 313041 12:16.08.08 - Selective
    [Show full text]
  • NINDS Custom Collection II
    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
    [Show full text]
  • The Role of Hydroxamic Acids in Biochemical Processes
    Biochemistry THE ROLE OF HYDROXAMIC ACIDS IN BIOCHEMICAL PROCESSES AHMED E. FAZARY* MOHAMED M. KHALIL** ALY FAHMY* TANTAWY A. TANTAWY* SUMMARY: Hydroxamic acids, a group of naturally occurring and synthetic weak organic acids of general formula RC(=O)N(R')OH, are widespread in the tissues of plants, in metabolites of bacteria and fungi, including complex compounds. Hydroxamic acids and their derivatives fulfill a variety of important roles in biology and medicine; here we provide a comprehensive brief review of the most basic medicinal chemistry and pharmacology of hydroxamate molecules. Key Words: Hydroxamic acids, biological activities, biochemical processes. INTRODUCTION INHIBITION EFFECT AND ANTICANCER ACTIVITY Since their discovery by Wahlroos and Virtanen (1) in OF HYDROXAMIC ACIDS 1959, and over the past decades, the chemistry and bio- The design and synthesis of ligands for biomedical chemistry of hydroxamic acids and their derivatives have applications in fields such as anticancer applications has attracted considerable attention, due to their pharmaco- become of great importance. One of these important lig- logical, toxicological and pathological properties. Hydrox- ands is hydroxamate molecules. Hydroxamic acids have amic acids generally have low toxicities and have a wide been found to react with both proteins and nucleic acids spectrum of activities in all types of biological systems, as (2). The reactivity of hydroxamic acids towards sulfhydryl such they act variously as growth factors, food additives, groups of proteins has been suggested to be the reason tumor inhibitors, antimicrobial agents, antituberculous, for their inhibitory effect on various enzymes. The pro- antileukemic agents, key pharmacophore in many impor- tease papain, for instance, with a single free cysteine tant chemotherapeutic agents, pigments and cell-division residue located at the active site was irreversibly inhibited factors.
    [Show full text]
  • Pharmaceuticals As Environmental Contaminants
    PharmaceuticalsPharmaceuticals asas EnvironmentalEnvironmental Contaminants:Contaminants: anan OverviewOverview ofof thethe ScienceScience Christian G. Daughton, Ph.D. Chief, Environmental Chemistry Branch Environmental Sciences Division National Exposure Research Laboratory Office of Research and Development Environmental Protection Agency Las Vegas, Nevada 89119 [email protected] Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Why and how do drugs contaminate the environment? What might it all mean? How do we prevent it? Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada This talk presents only a cursory overview of some of the many science issues surrounding the topic of pharmaceuticals as environmental contaminants Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada A Clarification We sometimes loosely (but incorrectly) refer to drugs, medicines, medications, or pharmaceuticals as being the substances that contaminant the environment. The actual environmental contaminants, however, are the active pharmaceutical ingredients – APIs. These terms are all often used interchangeably Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Office of Research and Development Available: http://www.epa.gov/nerlesd1/chemistry/pharma/image/drawing.pdfNational
    [Show full text]
  • A Multi-Biochemical and in Silico Study on Anti-Enzymatic Actions Of
    biomolecules Article A Multi-Biochemical and In Silico Study on Anti-Enzymatic Actions of Pyroglutamic Acid against PDE-5, ACE, and Urease Using Various Analytical Techniques: Unexplored Pharmacological Properties and Cytotoxicity Evaluation Miroslava Šudomová 1, Sherif T. S. Hassan 2,* , Haroon Khan 3 , Mahsa Rasekhian 4 and Seyed Mohammad Nabavi 5,* 1 Museum of literature in Moravia, Klášter 1, 664 61 Rajhrad, Czech Republic 2 Department of Natural Drugs, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences Brno, Palackého tˇr.1946/1, 612 42 Brno, Czech Republic 3 Department of Pharmacy, Abdul Wali Khan University, Mardan 23200, Pakistan 4 Pharmaceutical Sciences Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah 6734667149, Iran 5 Applied Biotechnology Research Center, Baqiyatallah University of Medical Sciences, Tehran 14359-16471, Iran * Correspondence: [email protected] (S.T.S.H.); [email protected] (S.M.N.); Tel.: +420-774-630-604 (S.T.S.H.) Received: 4 August 2019; Accepted: 20 August 2019; Published: 21 August 2019 Abstract: In the current study, pyroglutamic acid (pGlu), a natural amino acid derivative, has efficiently inhibited the catalytic activities of three important enzymes, namely: Human recombinant phosphodiesterase-5A1 (PDE5A1), human angiotensin-converting enzyme (ACE), and urease. These enzymes were reported to be associated with several important clinical conditions in humans. Radioactivity-based assay, spectrophotometric-based assay, and an Electrospray Ionization-Mass Spectrometry-based method were employed to ascertain the inhibitory actions of pGlu against PDE5A1, ACE, and urease, respectively. The results unveiled that pGlu potently suppressed the activity of PDE5A1 (half-maximal inhibitory concentration; IC50 = 5.23 µM) compared with that of standard drug sildenafil citrate (IC50 = 7.14 µM).
    [Show full text]
  • Malaysian Statistics on Medicines 2007
    MALAYSIAN STATISTICS ON MEDICINES 2007 Edited by: Faridah AMY, Sivasampu S, Lian LM, Hazimah H, Kok LC, Chinniah RJ With contributions from Lian LM, Tang RY, Hafizh AA, Hazimah H, Gan HH, Kok LC, Leow AY, Lim JY, Thoo S, Hoo LP, Faridah AMY, Lim TO, Sivasampu S, Nour Hanah O, Fatimah AR, Nadia Fareeda MG, Goh A, Rosaida MS, Menon J, Radzi H, Yung CL, Michelle Tan HP, Yip KF, Chinniah RJ, Khutrun Nada Z, Masni M, Sri Wahyu T, Jalaludin MY, Leow NCW, Norafidah I, G R Letchuman R, Fuziah MZ, Mastura I, Sukumar R, Yong SL, Lim YX, Yap PK, Lim YS, Sujatha S, Goh AS, Chang KM, Wong SP, Omar I, Alan Fong YY, David Quek KL, Feisul IM, Long MS, Christopher Ong WM, Ghazali Ahmad, Abdul Rashid Abdul Rahman, Hooi LS, Khoo EM, Sunita Bavanandan, Nur Salima Shamsudin, Puteri Juanita Zamri, Sim KH, Wan Azman WA, Abdul Kahar AG, Faridah Y, Sahimi M, Haarathi C, Nirmala J, Azura MA, Asmah J, Rohna R, Choon SE, Roshidah B, Hasnah Z, Wong CW, Noorsidah MY, Sim HY, J Ravindran, Nik Nasri, Ghazali I, Wan Abu Bakar, Tham SW, J Ravichandran, Zaridah S, W Zahanim WY, Intan SS, Tan AL, Malek R, Sothilingam S, Syarihan S, Foo LK, Low KS, Janet YH Hong, Tan ATB, Lim PC, Loh YF, Nor Azizah, Sim BLH, Mohd Daud CY, Sameerah SAR, Muhd Nazri, Cheng JT, Lai J, Rahela AK, Lim GCC, Azura D, Rosminah MD, Kamarun MK, Nor Saleha IT, Tajunisah ME, Wong HS, Rosnawati Yahya, Manjulaa DS, Norrehan Abdullah, H Hussein, H Hussain, Salbiah MS, Muhaini O, Low YL, Beh PK, Cardosa MS, Choy YC, Lim RBL, Lee AW, Choo YM, Sapiah S, Fatimah SA, Norsima NS, Jenny TCN, Hanip R, Siti Nor
    [Show full text]
  • Four-Tier Drug Benefit This Formulary List Provides Coverage Information About the Drugs Covered Under Our Four-Tier Pharmacy Plan
    Kaiser Permanente Hawaii PRESCRIPTION DRUG LIST Four-tier drug benefit This formulary list provides coverage information about the drugs covered under our Four-Tier Pharmacy Plan. The list is organized in alphabetical order and each drug name includes a color box that shows which tier the drug falls within. If your prescription drug is not on this list, it is not covered under our four-tier benefit structure. TIER 1 TIER 2 TIER 3 TIER 4 Specialty Generic drugs Generic drugs Brand-name drugs brand-name drugs on the published list. not included in Tier 1. on the published list. on the published list. Under the four-tier benefit structure, you pay a lower copayment for medically necessary generic medications and a higher copayment for specialty brand-name medications. Your copayments depend on your plan. For information about your prescription copayments, please review your Summary of Benefits. If your physician has prescribed a medically necessary generic medication, but you prefer to have the brand-name drug, you will pay the full member rate for the brand-name medication. Certain drugs may deviate from the four-tier benefit structure. See the following definitions for abbreviations linked to certain drugs on this list: • ACA = Under the Affordable Care Act (ACA), certain over-the-counter and prescription drugs are covered at no charge when prescribed by a physician for preventative purposes. • HCR = Certain Food and Drug Administration-approved contraceptive drugs and devices are available at no charge under health care reform (HCR). • PAH = There are some drugs that are covered only for pulmonary arterial hypertension (PAH).
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Appendix B - Product Name Sorted by Applicant
    JUNE 2021 - APPROVED DRUG PRODUCT LIST B - 1 APPENDIX B - PRODUCT NAME SORTED BY APPLICANT ** 3 ** 3D IMAGING DRUG * 3D IMAGING DRUG DESIGN AND DEVELOPMENT LLC AMMONIA N 13, AMMONIA N-13 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18 SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18 3M * 3M CO PERIDEX, CHLORHEXIDINE GLUCONATE * 3M HEALTH CARE INC AVAGARD, ALCOHOL (OTC) DURAPREP, IODINE POVACRYLEX (OTC) 3M HEALTH CARE * 3M HEALTH CARE INFECTION PREVENTION DIV SOLUPREP, CHLORHEXIDINE GLUCONATE (OTC) ** 6 ** 60 DEGREES PHARMS * 60 DEGREES PHARMACEUTICALS LLC ARAKODA, TAFENOQUINE SUCCINATE ** A ** AAA USA INC * ADVANCED ACCELERATOR APPLICATIONS USA INC LUTATHERA, LUTETIUM DOTATATE LU-177 NETSPOT, GALLIUM DOTATATE GA-68 AAIPHARMA LLC * AAIPHARMA LLC AZASAN, AZATHIOPRINE ABBVIE * ABBVIE INC ANDROGEL, TESTOSTERONE CYCLOSPORINE, CYCLOSPORINE DEPAKOTE ER, DIVALPROEX SODIUM DEPAKOTE, DIVALPROEX SODIUM GENGRAF, CYCLOSPORINE K-TAB, POTASSIUM CHLORIDE KALETRA, LOPINAVIR NIASPAN, NIACIN NIMBEX PRESERVATIVE FREE, CISATRACURIUM BESYLATE NIMBEX, CISATRACURIUM BESYLATE NORVIR, RITONAVIR SYNTHROID, LEVOTHYROXINE SODIUM ** TARKA, TRANDOLAPRIL TRICOR, FENOFIBRATE TRILIPIX, CHOLINE FENOFIBRATE ULTANE, SEVOFLURANE ZEMPLAR, PARICALCITOL ABBVIE ENDOCRINE * ABBVIE ENDOCRINE INC LUPANETA PACK, LEUPROLIDE ACETATE ABBVIE ENDOCRINE INC * ABBVIE ENDOCRINE INC LUPRON DEPOT, LEUPROLIDE ACETATE LUPRON DEPOT-PED KIT, LEUPROLIDE ACETATE ABBVIE INC * ABBVIE INC DUOPA, CARBIDOPA MAVYRET, GLECAPREVIR NORVIR, RITONAVIR ORIAHNN (COPACKAGED), ELAGOLIX SODIUM,ESTRADIOL,NORETHINDRONE ACETATE
    [Show full text]
  • Sharp Health Plan 2020 Formulary List of Covered Prescription Drugs
    2020 Formulary List of covered prescription drugs This drug list applies to all Large Group HMO and Large Group POS products, and the following Small Group HMO products: HMO GF 1, HMO GF 2, HMO GF 3, HMO GF 4, HMO GF 5, HMO GF 6, HMO GF 7, Bronze HDHP NG 1, CalChoice Bronze HDHP NG 3, CalChoice Bronze HMO NG 2, CalChoice Silver HMO NG 1, CalChoice Silver HMO NG 2, CalChoice Silver HMO NG 3, Silver HMO NG 1, Silver HMO NG 2, CalChoice Gold HMO NG 2, CalChoice Gold HMO NG 3, CalChoice Gold HMO NG 5, Gold HMO NG 1, Gold HMO NG 2, Gold HMO NG 3, Gold HMO NG 4, Gold HMO NG 5, Gold HMO NG 6, Gold HMO NG 7, CalChoice Platinum HMO NG 1, CalChoice Platinum HMO NG 2, CalChoice Platinum HMO NG 3, Platinum HMO NG 1, Platinum HMO NG 2, Platinum HMO NG 3, Platinum HMO NG 4, Platinum HMO NG 7, Platinum HMO NG 8 List of covered prescription drugs for Employer-sponsored plans from Sharp Health Plan An electronic version of this Prescription Drug List is available on the Sharp Health Plan website, by visiting sharphealthplan.com/search-drug-list You can find specific cost sharing information in your plan’s coverage documents by logging in to your Sharp Connect account on our website by visiting sharphealthplan.com/login This document is subject to change and all previous versions are no longer in effect. Last updated 12/01/2020. Table of Contents Introduction i-xii Definitions i How often does the Formulary change? iii Will I be notified of a Formulary change? iii How do I locate a Prescription Drug on the Formulary? iv How do I know if the drug listed
    [Show full text]
  • Perioperative Medication Management - Adult/Pediatric - Inpatient/Ambulatory Clinical Practice Guideline
    Effective 6/11/2020. Contact [email protected] for previous versions. Perioperative Medication Management - Adult/Pediatric - Inpatient/Ambulatory Clinical Practice Guideline Note: Active Table of Contents – Click to follow link INTRODUCTION........................................................................................................................... 3 SCOPE....................................................................................................................................... 3 DEFINITIONS .............................................................................................................................. 3 RECOMMENDATIONS ................................................................................................................... 4 METHODOLOGY .........................................................................................................................28 COLLATERAL TOOLS & RESOURCES..................................................................................................31 APPENDIX A: PERIOPERATIVE MEDICATION MANAGEMENT .................................................................32 APPENDIX B: TREATMENT ALGORITHM FOR THE TIMING OF ELECTIVE NONCARDIAC SURGERY IN PATIENTS WITH CORONARY STENTS .....................................................................................................................58 APPENDIX C: METHYLENE BLUE AND SEROTONIN SYNDROME ...............................................................59 APPENDIX D: AMINOLEVULINIC ACID AND PHOTOTOXICITY
    [Show full text]
  • Prescription Drug List
    Kaiser Permanente Hawaii PRESCRIPTION DRUG LIST Four-tier drug benefit This formulary list provides coverage information about the drugs covered under our Four-Tier Pharmacy Plan. The list is organized in alphabetical order and each drug name includes a color box that shows which tier the drug falls within. If your prescription drug is not on this list, it is not covered under our four-tier benefit structure. TIER 1 TIER 2 TIER 3 TIER 4 Generic drugs Generic drugs Brand-name drugs Specialty drugs on the published list. not included in Tier 1. on the published list. on the published list. Under the four-tier benefit structure, you pay a lower copayment for medically necessary generic medications and a higher copayment for specialty medications. Your copayments depend on your plan. For information about your prescription copayments, please review your Summary of Benefits. If your physician has prescribed a medically necessary generic medication, but you prefer to have the brand-name drug, you will pay the full member rate for the brand-name medication. Certain drugs may deviate from the four-tier benefit structure. See the following definitions for abbreviations linked to certain drugs on this list: • ACA = Under the Affordable Care Act (ACA), certain over-the-counter and prescription drugs are covered at no charge when prescribed by a physician for preventative purposes. • HCR = Certain Food and Drug Administration-approved contraceptive drugs and devices are available at no charge under health care reform (HCR). • PAH = There are some drugs that are covered only for pulmonary arterial hypertension (PAH). • TC = There are no charges for approved tobacco cessation (TC) products.
    [Show full text]